Literature DB >> 1546146

Epidemiology of depression.

J Angst1.   

Abstract

Review of the published literature produces 1-year prevalence rates for major depressive disorder DSM-III between 2.6 and 6.2%, for dysthymia between 2.3 and 3.7%, bipolar disorder 1.0-1.7%. Data from the prospective Zurich Study with four interviews over 10 years give relatively high 10-year prevalence rates for subjects from age 20 to 30 (14.4% major depression, 10.5% recurrent brief depression, 0.9% dysthymia, 3.3% bipolar disorder, 1.3% hypomania). On average, 49% of all these cases received treatment for affective disorder, resulting in a weighted treatment prevalence rate of the population of 11.6% (18% for females and 5% for males). It has to be assumed that lifetime prevalence rates based on recall may greatly underestimate true morbidity.

Entities:  

Mesh:

Year:  1992        PMID: 1546146     DOI: 10.1007/bf02246240

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  23 in total

1.  [The course of treated and untreated depressions and anxiety disorders. A clinico-psychiatric and epidemiological follow-up study].

Authors:  H U Wittchen; D von Zerssen
Journal:  Monogr Gesamtgeb Psychiatr Psychiatry Ser       Date:  1988

2.  Treatment planning. Dysthymic disorder complicated by bouts of major depression.

Authors:  A Frances; C B Voss
Journal:  Hosp Community Psychiatry       Date:  1987-05

3.  National Institute of Mental Health Diagnostic Interview Schedule. Its history, characteristics, and validity.

Authors:  L N Robins; J E Helzer; J Croughan; K S Ratcliff
Journal:  Arch Gen Psychiatry       Date:  1981-04

4.  The design of the Epidemiologic Catchment Area surveys. The control and measurement of error.

Authors:  W W Eaton; C E Holzer; M Von Korff; J C Anthony; J E Helzer; L George; A Burnam; J H Boyd; L G Kessler; B Z Locke
Journal:  Arch Gen Psychiatry       Date:  1984-10

5.  Recurrent brief depression: a new subtype of affective disorder.

Authors:  J Angst; K Merikangas; P Scheidegger; W Wicki
Journal:  J Affect Disord       Date:  1990-06       Impact factor: 4.839

6.  Prevalence of depression in an elderly population in Finland.

Authors:  S L Kivelä; K Pahkala; P Laippala
Journal:  Acta Psychiatr Scand       Date:  1988-10       Impact factor: 6.392

7.  Research diagnostic criteria: rationale and reliability.

Authors:  R L Spitzer; J Endicott; E Robins
Journal:  Arch Gen Psychiatry       Date:  1978-06

8.  Lifetime prevalence of psychiatric disorders in Edmonton.

Authors:  R C Bland; H Orn; S C Newman
Journal:  Acta Psychiatr Scand Suppl       Date:  1988

9.  Affective disorders and depression as measured by the Diagnostic Interview Schedule and the Beck Depression Inventory in an unselected adult population.

Authors:  J M Oliver; M E Simmons
Journal:  J Clin Psychol       Date:  1985-07

10.  The Zurich Study. XI. Is dysthymia a separate form of depression? Results of the Zurich Cohort Study.

Authors:  J Angst; W Wicki
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  1991       Impact factor: 5.270

View more
  17 in total

1.  False beliefs: the current treatment of patients with depression.

Authors:  Yves Lecrubier
Journal:  Curr Psychiatry Rep       Date:  2003-12       Impact factor: 5.285

Review 2.  QALYs and mental health care.

Authors:  D Chisholm; A Healey; M Knapp
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  1997-02       Impact factor: 4.328

3.  Cost utility of maintenance treatment of recurrent depression with sertraline versus episodic treatment with dothiepin.

Authors:  E J Hatziandreu; R E Brown; D A Revicki; R Turner; J Martindale; S Levine; J E Siegel
Journal:  Pharmacoeconomics       Date:  1994-03       Impact factor: 4.981

Review 4.  Paroxetine. A pharmacoeconomic evaluation of its use in depression.

Authors:  M I Wilde; R Whittington
Journal:  Pharmacoeconomics       Date:  1995-07       Impact factor: 4.981

5.  A Markov process analysis comparing the cost effectiveness of maintenance therapy with citalopram versus standard therapy in major depression.

Authors:  M J Nuijten; M Hardens; E Souêtre
Journal:  Pharmacoeconomics       Date:  1995-08       Impact factor: 4.981

Review 6.  Sertraline. A pharmacoeconomic evaluation of its use in depression.

Authors:  R Davis; M I Wilde
Journal:  Pharmacoeconomics       Date:  1996-10       Impact factor: 4.981

Review 7.  Fluoxetine. A pharmacoeconomic review of its use in depression.

Authors:  M I Wilde; P Benfield
Journal:  Pharmacoeconomics       Date:  1998-05       Impact factor: 4.981

8.  Emotions as infectious diseases in a large social network: the SISa model.

Authors:  Alison L Hill; David G Rand; Martin A Nowak; Nicholas A Christakis
Journal:  Proc Biol Sci       Date:  2010-07-07       Impact factor: 5.349

Review 9.  The need for an iterative process for assessing economic outcomes associated with SSRIs.

Authors:  T L Skaer; D A Sclar; L M Robison; R S Galin
Journal:  Pharmacoeconomics       Date:  2000-09       Impact factor: 4.981

10.  Lifetime prevalence estimates of major depression: an indirect estimation method and a quantification of recall bias.

Authors:  Michelle Elisabeth Kruijshaar; Jan Barendregt; Theo Vos; Ron de Graaf; Jan Spijker; Gavin Andrews
Journal:  Eur J Epidemiol       Date:  2005       Impact factor: 8.082

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.